The abstracts presented in this session advance our understanding of alcohol-associated liver disease (ALD) through cutting-edge research utilizing both mouse and human models. The session highlights key mechanisms and mediators of ALD, including oxidative stress, inflammation, and the gut-liver axis. It also explores the interplay between the liver and adipose tissue, the impact of environmental factors, and the potential of GLP1 as a therapeutic target. The objective is to foster discussion and collaboration around these diverse yet interconnected pathways to inform future research and treatment strategies.

This session will examine the intersection of chronic hepatitis B with metabolic risk factors, pharmacologic exposures, and evolving biomarkers in liver disease progression and surveillance. Topics will include the protective association of statins with HCC risk, the impact of hepatitis B on fibrosis in MASLD and the impact of GLP-1 on outcomes in HBV. Additional talks will address the potential for HBsAg quantification to define thresholds for discontinuing HCC surveillance and global progress toward HBV elimination targets.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

This abstract parallel session features a series of reports on the exploration of new agents in AIH and PBC, along with intriguing data on enhanced monitoring in cholestatic disorders.  

The myriad of imaging and allied tests available to evaluate known or sustpected liver disease and liver cancers can be bewildering.  In this session several of these techniques, including MRI, ultrasound, elastography and prognostic scores are considered.  

Deeper investigations into the pathogenesis of AIH, PBC and PSC requires application of novel tools.  This session highlights new discoveries in human and pre-clinical models of autoimmune and cholestatic disorders by the application of modern sophisticated analyses.

This session highlights the vital contributions of associates and advanced practice providers (APPs) in advancing hepatology care through real-world insights, innovative treatment strategies, and impactful quality improvement initiatives. Through data-driven research and patient-centered approaches, these presenters demonstrate the power of associate- and APP-led initiatives to improve outcomes and expand access in diverse clinical settings.

This abstract parallel session explores the complex relationship between metabolic dysfunction and alcohol-associated liver disease (ALD), with a focus on emerging clinical insights and risk stratification strategies. The included research abstracts examine the natural history and progression of ALD in the context of metabolic comorbidities, particularly following bariatric surgery. Key objectives include evaluating the risks and potential mitigators of ALD in post-surgical populations and assessing the effectiveness of population-based tools for early identification and risk stratification. The session will inform clinical decision-making and guide future research directions in the management of ALD.

This session highlights innovations from molecular mechanisms to drug development and clinical trials in biliary physiology and genetic and metabolic conditions. This session will spotlight cholangiocyte biology from scaffolding to repair. These research presentations will provide insights into mechanisms and therapeutics for A1AT deficiency, Wilson Disease, and hemachromatosis.